- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05448196
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Many financial support services are available to patients at the ACC, but are offered by different umbrella departments and rely on self- or clinician-referrals. Financial Advocacy provides assistance with insurance benefits, copayment assistance and hospital-based financial support. Social work assists with costs not directly related to treatment and also connects patients with community resources. Programs that increase coordination between these departments and proactively screen patients for financial hardship may enhance the reach of available services. However, such programs are resource intensive. As such, obtaining a better understanding of their benefits and any barriers to their expansion is a necessary first step to their broader implementation.
The long-term goal is to implement evidence-based practices that reduce ACC patients' financial burden. The overall objective of this proposal is to develop and evaluate a coordinated financial navigation program at the ACC for patients with multiple myeloma and identify barriers to its broader implementation. The rationale is that understanding the program's effectiveness and any barriers to its scalability will guide the way in which it could be incorporated into existing ACC workflows to maximize benefit for patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Patients actively receiving systemic therapy at the ACC, defined as receiving any anti-myeloma treatment and at least monthly follow-up at PCAM4 or one of our satellite locations (CCH, Princeton, Lancaster, Cherry Hill, Valley Forge, Radnor)
- These patients will be approached/recruited in-person on the same date as their return visit (follow-up appointment for established patients)
- These patients may have already been seen by FA/SW (we will record this information and control for this in the final statistical models)
The rationale for using the "follow up at least monthly" criterion is because it will allow our research coordinators to easily and readily review charts of patients scheduled for follow up with myeloma specialists. This strategy will only exclude patients who receive oral maintenance anti-myeloma therapy who follow up less than once monthly (e.g. lenalidomide maintenance only).
2. New patients expected to start therapy, who are expected to meet criterion #1.
- These patients will be approached/recruited at their first return visit.
- If these patients are not expected to return within 2 weeks of the initial visit, a telephone consent will be considered/offered
Exclusion Criteria:
o Have completed induction treatment and have stopped all systemic treatment in preparation for an autologous stem cell transplant [SCT] (rationale: patients are pre-screened for being able to finance their transplant before proceeding)
- Are referred only for autologous SCT (they would not qualify by criterion #1, anyway)
- Actively receive systemic therapy but do not follow up more than once monthly
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program.
This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups.
All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake.
The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs).
Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment.
The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
|
Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program.
This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups.
All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake.
The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs).
Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment.
The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
|
No Intervention: Usual Care
Patients are connected to financial advocacy and social work on an ad hoc basis, rather than systematically.
We hypothesize that many patients who would qualify and benefit from these services are not using them or are being referred late in their treatment course, which is contributing to their financial hardship and adversely affecting their healthcare.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
COmprehensive Score for Financial Toxicity (COST)
Time Frame: 4 months
|
Primary outcome is assessing for change in participants' COmprehensive Score for Financial Toxicity (COST) from the baseline assessment to repeat assessment after 4 months of financial navigation.
Scores range from 0-44, with lower scores representing greater financial hardship.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy (FACT-G)
Time Frame: 4 months
|
Secondary outcome is assessing for change in participants' Health Related Quality of Life (HRQOL) as measured in part by the Functional Assessment of Cancer Therapy (FACT-G) from the baseline assessment to repeat assessment after 4 months of financial navigation.
The FACT-G includes 4 subscales (physical well-being, social/family well-being, emotional well-being, and functional well-being).
The score ranges from 0-108 with a higher score indicating better quality of life.
|
4 months
|
Patient Satisfaction Questionnaire Short-Form [PSQ-18]
Time Frame: 4 months
|
Secondary outcome is assessing for change in participants' HRQOL as measured in part by the Patient Satisfaction Questionnaire Short-Form [PSQ-18] from the baseline assessment to repeat assessment after 4 months of financial navigation.
The PSQ-18 includes 7 subscales (general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and convenience).
The score ranges from 18-90 points with higher scores indicating increased patient satisfaction.
|
4 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Edward Stadtmauer, MD, Penn Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- UPCC 39421
- 850241 (Other Identifier: Penn Medicine)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Coordinated Financial Navigation Program
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMalignant Solid NeoplasmUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingNeoplasms | CarcinomaUnited States
-
Fudan UniversityRecruitingBreast Neoplasm Female | Financial Toxicity | Financial NavigationChina
-
Columbia UniversityPatient Advocate FoundationRecruitingCancer in AdolescenceUnited States
-
Tufts Medical CenterThe Leukemia and Lymphoma SocietyActive, not recruitingCancer | Financial Stress | SurvivorshipUnited States
-
Seattle Children's HospitalHarvard Pilgrim Health CareNot yet recruitingType 1 Diabetes
-
University of California, IrvineRecruiting
-
Rush University Medical CenterNational Institute of Nursing Research (NINR)Completed
-
Northwestern UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingContraception | Breastfeeding | Preventive Care / Anticipatory Guidance | Retention in Care | Postpartum HealthUnited States